Skip to Content
Merck
  • C/ebpα represses the oncogenic Runx3-Myc axis in p53-deficient osteosarcoma development.

C/ebpα represses the oncogenic Runx3-Myc axis in p53-deficient osteosarcoma development.

Oncogene (2023-07-05)
Keisuke Omori, Shohei Otani, Yuki Date, Tomoya Ueno, Tomoko Ito, Masahiro Umeda, Kosei Ito
ABSTRACT

Osteosarcoma (OS) is characterized by TP53 mutations in humans. In mice, loss of p53 triggers OS development, and osteoprogenitor-specific p53-deleted mice are widely used to study the process of osteosarcomagenesis. However, the molecular mechanisms underlying the initiation or progression of OS following or parallel to p53 inactivation remain largely unknown. Here, we examined the role of transcription factors involved in adipogenesis (adipo-TFs) in p53-deficient OS and identified a novel tumor suppressive molecular mechanism mediated by C/ebpα. C/ebpα specifically interacts with Runx3, a p53 deficiency-dependent oncogene, and, in the same manner as p53, decreases the activity of the oncogenic axis of OS, Runx3-Myc, by inhibiting Runx3 DNA binding. The identification of a novel molecular role for C/ebpα in p53-deficient osteosarcomagenesis underscores the importance of the Runx-Myc oncogenic axis as a therapeutic target for OS.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
HLM006474, ≥98% (HPLC)